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RESUMEN
Objetivo: Unir atenolol, antagonista selectivo de los receptores β1, y desloratadina, antagonista de los 
receptores H1, a albúmina sérica bovina.
Método: El análisis de la unión se analizó mediante diálisis de equilibrio utilizando ranitidina y 
diazepam como sondas específicas para el sitio I y sitio II respectivamente 
Resultados: Los resultados sugirieron dos conjuntos de constantes de asociación. Para el atenolol: 
constante de asociación con afinidad elevada (k1 = 5 x 10-5 M-1) con baja capacidad (n1 = 2) y constante 
de asociación con afinidad baja (k2 = 5 x 10-5 M-1) con alta capacidad (n2 = 5), mientras que para la 
desloratadina: constante de afinidad de asociación elevada (k1 = 45 x 10-5 M-1) con baja capacidad (n1 = 
1,3) y constante de afinidad de asociación baja (k2= 5 x 10-5 M-1) con alta capacidad (n2 = 2,5), a un pH 7,4 
y 27 °C. Tras la administración conjunta de atenolol y desloratadina en presencia o ausencia de ranitidina 
o diazepam, la desloratadina provocó la liberación del atenolol de su sitio de unión a la albúmina sérica 
bovina, provocando una disminución de la unión del atenolol a la albúmina sérica bovina. La fracción 
libre de atenolol incrementó del 84,1% al 99% y la concentración de la desloratadina de 0 x 10-5 M a 14 x 
10-5 M. En presencia de diazepam como sonda específica para el sitio II, la desloratadina incrementó la 
fracción libre de atenolol del 0,45% to 14,3%.
Conclusión: Los datos obtenidos indican la interacción de concentraciones elevadas de desloratadina 
a los sitios de unión de la albúmina sérica bovina modificando las propiedades farmacocinéticas del 
atenolol. 
PALABRAS CLAVE: Atenolol, desloratadine, drug-drug interaction, bovine serum albumin, 
equilibrium dialysis
ABSTRACT 
Aims: The binding of atenolol a selective β1 receptor antagonist and desloratadine, an H1 receptor 
antagonist, to bovine serum albumin. 
Methods: The analysis of binding was studied by equilibrium dialysis method (ED) using ranitidine 
and diazepam as site-1 and site-2 specific probe, respectively.
Results:  The study suggested two sets of association constants, for atenolol: high affinity association 
constant (k1 = 5 x 10-5 M-1) with low capacity (n1 = 2) and low affinity association constant (k2 = 2.5 
x 10-5 M-1) with high capacity (n2 = 5), while for desloratadine: high affinity association constant (k1 
= 45 x 10-5 M-1) with low capacity (n1 = 1.3) and low affinity association constant (k2 = 5 x 10-5 M-1) 
with high capacity (n2 = 2.5) at pH 7.4 and 27 °C. During concurrent administration of atenolol and 
desloratadine in presence or absence of ranitidine or diazepam, desloratadine causes the release of 
atenolol from its binding site on BSA resulting reduced binding of atenolol to BSA. The increment in 
free fraction of atenolol was from 84.01% to 99 % upon the addition of increased concentration of only 
desloratadine at a concentration of 0 x 10-5 M to 14 x 10-5 M. In presence of diazepam as site-II specific 
probes, desloratadine further increases the free fraction of atenolol was from 0.45% to 14.3%.
Conclusion: These data were indicative for the interaction of higher concentration of desloratadine at 
the binding sites on BSA changing the pharmacokinetics properties of atenolol.
KEY WORDS: Atenolol, desloratadine, drug-drug interaction, bovine serum albumin, equilibrium dialysis
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INTRODUCTION
Atenolol, a selective β1 receptor antagonist, is used in the 
management of hypertension1-3; while desloratadine, a 
tricyclic H1-antagonist, is a drug used to treat allergic and 
other related symptoms4-6. This is a very used practice to 
co-prescribe atenolol and desloratadine for the patient. 
Hence, the concurrent administration of these two drugs 
is supposed to modulate the pharmacokinetic profiles such 
as protein binding, volume of distribution, elimination of 
each other. 
Pharmacokinetic studies revealed that atenolol is 
incompletely absorbed from oral dosage forms and the 
bioavailability is approximately 50% due to reduced 
absorption. After oral administration peak blood levels 
are observed at 2-4 h and elimination half life of atenolol 
is calculated from 6 to 9 h by different authors. In plasma 
only 3% of atenolol are protein-bound7-9. Although 
marked interactions of atenolol are found when calcium 
or aluminium hydroxide are concurrently administered 
with the beta blocker10. Rifampicin has also reported to 
affect the pharmacokinetics slightly by a slight reduction 
in its bioavailability11. Orange juice moderately reduce the 
bioavailability of atenolol by interfering with its absorption 
from the gastrointestinal tract12. Another studies showed 
that amlodipine displaces atenolol in-vitro from its binding 
sites13. Interactions of valsartan and atenolol have also been 
reported following single doses14.
On the other hand it has been reported that the protein 
binding of desloratadine is 85-89%. The mean elimination 
half-life of Desloratadine was 27 hours15-17. No significant 
interactions of desloratadine with food materials are 
reported18. However, there is lack of sufficient reports 
on pharmacokinetic interactions of B-blockers with 
antihistaminic drugs administered concurrently.
Since, plasma protein binding properties are primarily 
determinants of the pharmacokinetic properties of most 
of the drugs, such as plasma clearance, half-life, apparent 
volume of distribution and the duration and intensity of 
pharmacologic effect19,20. Drug displacement also affects 
other aspects of drug deposition, such as, metabolism and 
excretion21. Therefore, the present study was undertaken 
to characterize the binding profiles of atenolol as well as 
to notify the interaction of desloratadine with atenolol at 
its binding site on albumin using bovine serum albumin 
employing equilibrium dialysis methods.
Our studies revealed that binding of atenolol with two sets 
of association constant: high affinity association constant 
with low capacity and low affinity association constant 
with high capacity. Site specific probe displacement study 
implied that atenolol bind to site II, the diazepam site. 
However, it has low binding affinity to site I on BSA. While, 
concurrent administration of desloratadine significantly 
modulates binding of atenolol to BSA. Desloratadine 
displaced Atenolol from its binding site of BSA.
MATERIALS AND METHODS
Materials and instruments
Dialysis membrane (molecular weight cut off at 3500 
Daltons) and bovine serum albumin (fatty acid free, 
fraction V, 96-98%) used in the experiment were purchased 
from Medicell International Ltd., UK and Sigma Chemical 
Co., USA, respectively. Atenolol, desloratadine, ranitidine 
hydrochloride and diazepam were kind gift from a local 
pharmaceutical company of Bangladesh. Disodium 
hydrogen phosphate (Na2HPO4), potassium dihydrogen 
phosphate (KH2PO4), were obtained from Glaxo; U.K. 
High-resolution UV-VIS spectrophotomer (SP8-400 UV/
VIS Spectrophotometer, Thermospectronic, England.) and 
Metabolic Shaking Incubator (Clifton Shaking Bath, Nickel 
Electro Ltd., England.) were used in the experiment. All 
other chemicals used in the experiment were of commercial 
grade. Equilibrium Dialysis method was employed in this 
study. Dialysis membrane used in the experiment was cut 
into small pieces and was boiled for 8 hours at 65-70 °C in 
de-ionized water to remove sulfur.
Preparation of standard curve
Standard calibration curve was prepared following the 
methods reported before19. Briefly, for the preparation 
of standard curves of ranitidine hydrochloride, 
diazepam, atenolol, desloratadine, solutions of different 
concentrations (0×10-5 M to 10×10-5 M) of these drugs were 
prepared in phosphate buffer of 7.4 and taking absorbance 
values at determined λ max 318 nm, 235 nm,  273 nm and 
242 nm, respectively. Standard curves were obtained by 
plotting the absorbance values against the corresponding 
the concentrations.
Estimation of association constant 
To determine the association constant of atenolol, different 
concentrations (2×10-5 M to 8×10-5 M) of atenolol solutions 
were mixed with prepared BSA solution (2×10-5 M in 
phosphate buffered saline, pH 7.4) to get a final volume 
of 5 ml each. These solutions were allowed to stand for 
sometime for the maximum binding of atenolol to BSA. 
From each mixture, 3.5 ml of solution was withdrawn 
and poured into previously prepared semi-permeable 
membrane tubes and both sides of the membranes were 
sealed properly as there was no leakage. The membrane 
tubes containing drug-protein mixture were immersed in 
conical flasks containing 30 ml of phosphate buffer (pH 7.4) 
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and were placed in a metabolic shaker for dialysis for 12 
hours (27 °C, 20 rpm). Buffer samples were collected from 
each conical flask after dialysis and free fraction of atenolol 
was measured by UV spectrophotometer (λ max 273 nm). 
Determination of binding site of atenolol using ranitidine 
as site-I specific probe
To determine the binding sites of atenolol at BSA, the 
concentrations of BSA and probe (ranitidine hydrochloride 
as site-I specific probe) were remained fixed in 1:1 ratio 
(2×10-5 M: 2×10-5 M) and the concentration of atenolol was 
added in increased concentration (0 to 16×10-5 M). So, the 
final ratio of BSA: Probe: atenolol were 1:1:0, 1:1:4, 1:1:6, 
1:1:8. The dialysis was carried out as described above and 
free fraction of ranitidine hydrochloride was measured at 
λ max 318 nm. Only BSA solution and mixture of BSA and 
atenolol were used as positive and negative control during 
the measurement. 
Determination of binding site of atenolol using diazepam 
as site-II specific probe
The binding sites of atenolol at BSA, using diazepam as 
site-II specific probe, were determined employing the 
same methods as described above. Briefly, BSA: diazepam: 
atenolol were mixed at 1:1:0, 1:1:1, 1:1:2, 1:1:4. The dialysis 
was carried out as described above and free concentration 
of diazepam was measured at λ max 235 nm. Alternatively, 
BSA: atenolol: diazepam were taken as 1:1:0, 1:1:1, 1:1:2, 
1:1:4. After dialysis, free concentration of atenolol was 
measured at λ max 273 nm. Negative and positive controls 
were maintained in both cases of measurements.
Determination of binding site of desloratadine using 
ranitidine as site-I specific probe
For the determination of the binding sites of desloratadine 
at BSA, the concentrations of BSA and probe (ranitidine 
hydrochloride as site-I specific probe) were remained fixed 
in 1:1 ratio (2×10-5 M: 2×10-5 M) and the concentration of 
desloratadine was added in increased concentration (0 to 
12×10-5 M). So, the final ratio of BSA: Probe: desloratadine 
were 1:1:0, 1:1:2, 1:1:4, 1:1:6. The dialysis was carried 
out as described above and free fraction of ranitidine 
hydrochloride was measured at λ max 318 nm. Only BSA 
solution and mixture of BSA and atenolol were used 
positive and negative control during the measurement. 
Determination of binding site of desloratadine using 
diazepam as site-II specific probe
The binding sites of desloratadine at BSA, using diazepam 
as site-II specific probe, were determined employing the 
same methods as describe above. Briefly, BSA: diazepam: 
desloratadine were mixed at 1:1:0, 1:1:1, 1:1:2, 1:1:4, 1:1:6. 
The dialysis was carried out as described above and free 
concentration of diazepam was measured at λ max 235 
nm. Alternatively, BSA: desloratadine: diazepam were 
taken as 1:1:0, 1:1:1, 1:1:2, 1:1:4, 1:1:6. After dialysis, free 
concentration of desloratadine was measured at λ max 242 
nm. Negative and positive controls were maintained in 
both cases of measurements.
Effect of desloratadine on atenolol binding to BSA
The effect of desloratadine on atenolol, when bound to 
BSA was estimated in absence and in presence of site 
specific probes using ranitidine as site-I specific and 
diazepam as site-II specific probes, respectively. In absence 
of site specific probes, the BSA and atenolol was mixed 
at 1:1 ratio (2 x10-5 M: 2 x 10-5 M) and then desloratadine 
was added in increasing concentration (0 to 14 x 10-5 M) 
to make final ratio of BSA, atenolol and desloratadine in 
each experiment as 1:1:0, 1:1:1, 1:1:3, 1:1:5 and 1:1:7. While 
in presence of probes; BSA, probe and atenolol were 
mixed at ratio of 1:2:1 and desloratadine was added in 
increasing concentration to make the final ratio of protein, 
probe, atenolol and desloratadine as 1:2:1:0, 1:2:1:1, 1:2:1:3, 
1:2:1:5, 1:2:1:7. Dialysis was carried out and the amount of 
free atenolol was measured in absence and in presence of 
probes as described above. Only BSA was used as positive 
control, mixture of BSA and desloratadine, and mixture 
of BSA, desloratadine and probe were used as negative 
control.
RESULTS
Estimation of binding parameters
Scatchard analysis of the binding of the drugs at pH 7.4 
and at 27° C provided a non-liner curve, suggesting the 
presence of at least two classes of binding sites for the 
binding of atenolol and desloratadine to BSA (Figure 1A and 
1B). Figure 1A shows that the number of high affinity 
binding site (n1) for atenolol was approximately two 
(low capacity) and the number of low affinity binding 
site (n2) was approximately five (high capacity). The 
high affinity association constant (kl) for the atenolol 
binding to BSA at pH 7.4 is quite high (5.2 x 10-5 M-1), 
while the low affinity association constant (k2) for this drug 
to BSA is about 2 fold lower (2.5 x 10-5 M-1) than that of 
primary association constant. While Figure 1B shows 
that the number of high affinity binding site (n1) for 
desloratadine was approximately one (low capacity) 
and the number of low affinity binding site (n2) was 
approximately two (high capacity). The high affinity 
association constant (kl) for the desloratadine binding 
to BSA at pH 7.4 is very high (45 x 10-5 M-1), while the 
low affinity association constant (k2) for this drug to BSA 
is about 9 fold lower (5 x 10-5 M-1) than that of primary 
Ars Pharm. 2012; 53(4): 21-27.
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Figure 1. Scatchard plot for the binding of atenolol (A) 
and desloratadine (B) to BSA by equilibrium dialysis 
at pH 7.4 and 27 °C. The drugs [0 x 10-5 M to 8 x 10-5 
M] were added to BSA [2 x 10-5 M] and dialyzed as 
described under materials and methods. Free fraction 
of drugs were measured by UV-spectroscopic method 
and analyzed.
Figure 2. Free fraction of ranitidine (●) or diazepam 
(■) bound to BSA (1:1) as % of initial upon the 
addition of atenolol by equilibrium dialysis at 27 °C 
and pH 7.4.
Figure 3. Free fraction of ranitidine (●) or diazepam 
(■) bound to BSA (1:1) as % of initial upon the 
addition of desloratadine by equilibrium dialysis at 
27°C and   pH 7.4
Figure 4. Free fraction of atenolol (●) and desloratadine 
(■) bound to BSA (1:1) as % of initial upon the addition 
of diazepam by equilibrium dialysis at 27°C and pH 
7.4
Figure 5. Free fraction of atenolol (●) and desloratadine 
(■) bound to BSA (1:1) as % of initial upon the addition 
of diazepam by equilibrium dialysis at 27°C and pH 
7.4
Ars Pharm. 2012; 53(4): 21-27.
Shihab-us-Sakib K, Islam MA, Moniruzzaman M, Hussein A, Hossain M, Mazid MA.
25
association constant .These findings indicate higher binding 
affinity of desloratadine to BSA. 
Interaction of atenolol with site specific probes
The effects of atenolol on the binding of site specific probes 
were examined to determine whether atenolol binds 
preferentially with site-I or site-II on BSA. As mentioned 
under materials and methods, site specific probe and BSA 
were mixed at 1:1 molar ratio and atenolol was added in an 
increased concentration from 0 x 10-5 M to 16 x 10-5 M. The 
result showed that atenolol causes the decrement of free 
fraction of ranitidine from approximately 9.8% to 6% and 
increment of diazepam approximately from 14% to 40% 
(Figure 2). On the other hand diazepam increased the free 
fraction of atenolol from 0.65% to 0.95% (Figure 4).
Interaction of desloratadine with site specific probes
The effect of desloratadine was measured to know whether 
it can release the ranitidine and diazepam from their 
binding sites or not. It was found that desloratadine at 
a concentration from 0 x 10-5 M to 12 x 10-5 M decreased 
the free fraction ranitidine  approximately from 9.32% to 
4.96% and increased the free fraction of diazepam from 
approximately 13.52% to 24.40% (Figure 3). Alternatively 
diazepam increased the free fraction of desloratadine from 
2.8% to 12.45% (Figure 4).
Interaction of desloratadine with atenolol at the binding 
sites on BSA 
The interactions at bindings sites on BSA were studied 
between atenolol and desloratadine in the absence or in 
presence of site specific probes ranitidine and diazepam, 
respectively. In absence of both ranitidine and diazepam, 
desloratadine increased the free fraction of atenolol 
from approximately 84.01% to 99% with the addition of 
desloratadine from 0 x 10-5 M to 14 x 10-5 M (Figure 5). 
Whereas, in presence of diazepam as site specific probe, 
desloratadine at the same concentration, incremented the 
free fraction of atenolol from 0.45% to 14.3% (Figure 5). 
DISCUSSION
Binding of drugs are determined by studying its ability to 
displace the site specific probes. In this study ranitidine 
hydrochloride and diazepam were used as site-I and 
site-II specific probes, respectively. The association 
constants as shown in Table: 1 indicates that atenolol 
binds less preferentially to BSA than desloratadine. 
Figure 2 shows the change in free concentration of 
ranitidine and diazepam by atenolol. It is seen that 
the free concentration of ranitidine decreased from 
approximately 9.8% to 6%. whereas, Whereas, the free 
concentration of diazepam was increased approximately 
from 14% to 40% by the same drug. On the other hand 
the association constant as shown in Table: 1 indicates that 
desloratadine is highly bound to BSA. Figure 3 show the 
change in free concentration of ranitidine and diazepam 
by desloratadine. It is seen that the free concentration 
of ranitidine decreased from approximately 9.32% to 
4.96%. whereas, the free concentration of diazepam was 
increased from approximately from 13.52% to 24.40% by 
the same drug. From this observation it can be said that 
atenolol and desloratadine at higher concentration 
displaced diazepam to a greater extent as compared 
to ranitidine, so atenolol and desloratadine has greater 
affinity for site II than for site I on the BSA molecule. 
This implies the fact that at a lower drug to BSA ratio, 
atenolol binds to its high affinity site i.e., site II or the 
benzodiazepine site, whereas at higher ratio it does not only 
binds to its high affinity site but also to its low affinity site 
i.e., site I or the warfarin site on the BSA molecule.
The pharmacokinetic properties of drugs are influenced 
by exogenous as well as endogenous compounds by 
binding to serum albumin in a reversible manner19.  Here 
we, for the first time, reported the in vitro interaction of 
desloratadine with atenolol at the binding sites on BSA. 
Plasma protein binding properties are considered to be the 
primary determinants of the pharmacokinetic properties 
of many drugs. Therefore any alteration or change in the 
serum albumin binding of these drugs might lead to a 
change in the pharmacokinetic properties of these drugs. 
Figure 5 showed the change in the free concentration of 
atenolol bound to BSA in the presence of desloratadine 
with and without diazepam, the site II specific probe at pH 
Table 1.  Association constant of atenolol and desloratadine bound to BSA at pH 7.4 (27 oC)
Name of the drug pH Association constant
k1 (high affinity)×105M-1 k2 (low affinity)×105M-1
Atenolol 7.4 5 ± 0.07 2.5 ± 0.03
Desloratadine 7.4 45± 0.07 5 ± 0.03
Note: Value represents the mean ± SEM of three independent experiments
Ars Pharm. 2012; 53(4): 21-27.
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7.4 and at 27ºC. As observed in Figure 5, the free fraction 
of atenolol bound to BSA was increased from 84.01% to 
99% by desloratadine in the absence of diazepam. Whereas 
in Figure 5, in the presence of diazepam, this increment 
was from 0.45% to 14.3%. This suggests that atenolol is 
displaced by desloratadine in the presence of diazepam.
CONCLUSION
Serum albumin, the most abundant protein in blood 
plasma serves as a depot and transport protein for 
numerous endogenous and exogenous compounds22. The 
most outstanding property of albumin is its ability to bind 
reversibly an incredible variety of ligands including fatty 
acids, amino acids (tryptophan and cysteine), steroids, 
metals such as calcium, copper and zinc, and numerous 
pharmaceuticals23. Hence serum binding can be one of the 
determinants for the pharmacokinetics of drugs20,21. The 
binding of atenolol and desloratadine, antihypertensive 
and anti-histaminic drugs respectively, to bovine serum 
albumin (BSA) has been studied by equilibrium dialysis 
method at pH 7.4 in order to have an insight in the binding 
chemistry of the drug to BSA. We found that desloratadine, 
displaces atenolol from its binding sites on BSA. As 
there is strong analogy between BSA and (human serum 
albumin (HSA), it is assumed that similar types of binding 
characteristics will be exhibited by atenolol when bound to 
HSA. The pharmacologic activity of a drug is related to its 
protein binding. If a drug shows less affinity for albumin 
due to any alteration in protein binding, the pharmacologic 
effect of the drug may be significantly altered19,21. The 
results of the present study in combination with the current 
advances in the binding of atenolol and interaction with 
desloratadine might be helpful in realizing to the overall 
binding behavior of the drug with HSA. However, from 
our limited data it is too early to draw such conclusion 
about the changes of pharmacokinetic/pharmacological 
properties of the atenolol in presence of desloratidine. 
Further studies are deserved to get more detailed of the 
pharmacokinetic interactions using in vivo experimental 
model. 
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